<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945122</url>
  </required_header>
  <id_info>
    <org_study_id>2015-ZX26</org_study_id>
    <nct_id>NCT04945122</nct_id>
  </id_info>
  <brief_title>Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in AMI Patients With Abnormal Glucose Metabolism</brief_title>
  <acronym>CAPE-AMI</acronym>
  <official_title>Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in Acute Myocardial Infarction (AMI) Patients With Abnormal Glucose Metabolism: a Multicenter Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Difference types of statins show different influences on glycometabolism. There are no&#xD;
      systemic analyses of the effects that statins exert on the metabolism of glucoses so far in&#xD;
      China. This research aims to compare impacts on the glycometabolism of pitavastatin in AMI&#xD;
      patients with atorvastatin and to accumulate data for guiding the utilization of statins.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General study design:&#xD;
&#xD;
      This study is a prospective, multicenter, open and randomized controlled clinical trial,&#xD;
      which utilize online registration database of CAMI to do the enrollment, randomization and&#xD;
      follow-up. We will select 14 of the centers to compete into the group. The researchers used a&#xD;
      central randomized distribution system to prescribe medication for patients. Follow the&#xD;
      method of drug administration approved by the state drug administration department, we will&#xD;
      estimate the efficacy and safety of treatment at the following timing: baseline, one month&#xD;
      and six months after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c reduction</measure>
    <time_frame>six months after treatment</time_frame>
    <description>Comparing the impact on HbA1c of AMI patients with abnormal glucose metabolism using pitavastatin 4mg versus atorvastatin 20mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-c reduction</measure>
    <time_frame>six months after treatment</time_frame>
    <description>Comparing the absolute reduction of LDL-c level in AMI patients with abnormal glucose metabolism using pitavastatin 4mg versus atorvastatin 20mg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Pitavastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed AMI with abnormal glucose metabolism use pitavastatin (4mg po Qn) to control cholesterol for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients diagnosed AMI with abnormal glucose metabolism use atorvastatin (20mg po Qn) to control cholesterol for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Pitavastatin 4mg Qn</description>
    <arm_group_label>Pitavastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 20mg Qn</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed acute myocardial infarction.&#xD;
&#xD;
          2. Diabetes or pre-diabetes.&#xD;
&#xD;
          3. The patient signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A clear history of chronic liver disease, or abnormal liver function&#xD;
             (ALT/AST&gt;1.5×ULN).&#xD;
&#xD;
          2. There is evidence of active inflammatory myopathy or CK&gt;3×ULN.&#xD;
&#xD;
          3. Being allergic to statins or severe side effects were caused by taking&#xD;
             statins(including myolysis).&#xD;
&#xD;
          4. Combined with hypothyroidism, nephrotic syndrome, alcoholism, pancreatitis, lupus&#xD;
             erythematosus.&#xD;
&#xD;
          5. All patients who had a clear adverse reaction to the statins.&#xD;
&#xD;
          6. Possibility of pregnancy, pregnant or lactating patients.&#xD;
&#xD;
          7. There may be limited medical history of subjects who may can not complete their&#xD;
             treatment during the study period.&#xD;
&#xD;
          8. Undergoing or planning to functional renal transplantation.&#xD;
&#xD;
          9. The life expectancy is no more than half a year.&#xD;
&#xD;
         10. Patients who are taking birth control pills, steroid hormones and imidazole drugs.&#xD;
&#xD;
         11. Patients who have participated in clinical trials of other drugs within 1 month, or&#xD;
             known that clinical follow-up or research on drug compliance poorly.&#xD;
&#xD;
         12. Patients are not fit to be tested according to the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-jin Gao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-jin Gao, M.D.</last_name>
    <phone>+8613810644383</phone>
    <email>sophie_gao@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingang Yang, M.D.</last_name>
    <phone>+8613810821420</phone>
    <email>jingangyang@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-jin Gao, M.D.</last_name>
      <phone>+8613810644383</phone>
      <email>sophie_gao@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hoy SM. Pitavastatin: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168. doi: 10.1007/s40256-017-0213-8. Review.</citation>
    <PMID>28130659</PMID>
  </reference>
  <reference>
    <citation>Yoon D, Sheen SS, Lee S, Choi YJ, Park RW, Lim HS. Statins and risk for new-onset diabetes mellitus: A real-world cohort study using a clinical research database. Medicine (Baltimore). 2016 Nov;95(46):e5429. doi: 10.1097/MD.0000000000005429.</citation>
    <PMID>27861386</PMID>
  </reference>
  <reference>
    <citation>China Cholesterol Education Program (CCEP) Working Committee; Atherosclerosis Thrombosis Prevention and Control Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare; Cardiovascular Disease Subcommittee of China Association of Gerontology and Geriatrics; Atherosclerosis Professional Committee of Chinese College of Cardiovascular Physicians. [China cholesterol education program (CCEP) expert advice for the management of dyslipidaemias to reduce cardiovascular risk (2019)]. Zhonghua Nei Ke Za Zhi. 2020 Jan 1;59(1):18-22. doi: 10.3760/cma.j.issn.0578-1426.2020.01.003. Chinese.</citation>
    <PMID>31887831</PMID>
  </reference>
  <reference>
    <citation>Livingstone SJ, Looker HC, Akbar T, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Fuller JH, Colhoun HM. Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS). Diabetologia. 2016 Feb;59(2):299-306. doi: 10.1007/s00125-015-3802-6. Epub 2015 Nov 17.</citation>
    <PMID>26577796</PMID>
  </reference>
  <reference>
    <citation>Huang CH, Huang YY, Hsu BR. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. J Diabetes Investig. 2016 Sep;7(5):769-76. doi: 10.1111/jdi.12483. Epub 2016 Feb 22.</citation>
    <PMID>27181110</PMID>
  </reference>
  <reference>
    <citation>Nakagomi A, Shibui T, Kohashi K, Kosugi M, Kusama Y, Atarashi H, Shimizu W. Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia. J Atheroscler Thromb. 2015;22(11):1158-71. doi: 10.5551/jat.29520. Epub 2015 Jun 17.</citation>
    <PMID>26084792</PMID>
  </reference>
  <reference>
    <citation>Choi SH, Lim S, Hong ES, Seo JA, Park CY, Noh JH, Mok JO, Lee KY, Park JS, Kim DJ, Lee CB, Kim SR, Jang HC. PROPIT: A PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome. Clin Endocrinol (Oxf). 2015 May;82(5):670-7. doi: 10.1111/cen.12580. Epub 2014 Oct 17.</citation>
    <PMID>25109606</PMID>
  </reference>
  <reference>
    <citation>Cho Y, Choe E, Lee YH, Seo JW, Choi Y, Yun Y, Wang HJ, Ahn CW, Cha BS, Lee HC, Kang ES. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism. 2015 Apr;64(4):482-8. doi: 10.1016/j.metabol.2014.09.008. Epub 2014 Sep 28.</citation>
    <PMID>25312577</PMID>
  </reference>
  <reference>
    <citation>Baudrand R, Pojoga LH, Vaidya A, Garza AE, Vöhringer PA, Jeunemaitre X, Hopkins PN, Yao TM, Williams J, Adler GK, Williams GH. Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation. 2015 Nov 10;132(19):1825-33. doi: 10.1161/CIRCULATIONAHA.115.016759. Epub 2015 Oct 2.</citation>
    <PMID>26432671</PMID>
  </reference>
  <reference>
    <citation>Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl. 2015 Jan;16:1-27. doi: 10.1016/S1567-5688(14)70002-9. Review.</citation>
    <PMID>25575403</PMID>
  </reference>
  <reference>
    <citation>Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther. 2014 Aug 1;36(8):1211-22. doi: 10.1016/j.clinthera.2014.06.009. Epub 2014 Jul 3.</citation>
    <PMID>24998014</PMID>
  </reference>
  <reference>
    <citation>Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz I, Sukiennik A, Kelm M, De Servi S, Kubica J. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013 Apr 15;111(8):1123-30. doi: 10.1016/j.amjcard.2012.12.037. Epub 2013 Jan 24.</citation>
    <PMID>23352266</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.</citation>
    <PMID>23303884</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.</citation>
    <PMID>23295957</PMID>
  </reference>
  <reference>
    <citation>Warita S, Kawasaki M, Tanaka R, Ono K, Kojima T, Hirose T, Iwama M, Watanabe T, Nishigaki K, Takemura G, Noda T, Watanabe S, Minatoguchi S. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years' follow-up. Circ J. 2012;76(12):2755-62. Epub 2012 Aug 8.</citation>
    <PMID>22878405</PMID>
  </reference>
  <reference>
    <citation>Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther. 2011 May;9(5):555-62. doi: 10.1586/erc.11.47. Review.</citation>
    <PMID>21615316</PMID>
  </reference>
  <reference>
    <citation>Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22;305(24):2556-64. doi: 10.1001/jama.2011.860.</citation>
    <PMID>21693744</PMID>
  </reference>
  <reference>
    <citation>Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011 Nov;13(11):1047-55. doi: 10.1111/j.1463-1326.2011.01477.x.</citation>
    <PMID>21812889</PMID>
  </reference>
  <reference>
    <citation>Yoshika M, Komiyama Y, Masuda M, Yokoi T, Masaki H, Ohkura H, Takahashi H. Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists. Clin Exp Hypertens. 2010;32(6):341-6. doi: 10.3109/10641961003628460.</citation>
    <PMID>21028996</PMID>
  </reference>
  <reference>
    <citation>Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c332. doi: 10.1136/bmj.c332.</citation>
    <PMID>20332509</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Macfadyen JG, Nordestgaard BG, Koenig W, Kastelein JJ, Genest J, Glynn RJ. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for &quot;intermediate risk&quot;. Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):447-52. doi: 10.1161/CIRCOUTCOMES.110.938118. Epub 2010 Aug 24.</citation>
    <PMID>20736443</PMID>
  </reference>
  <reference>
    <citation>Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008 Oct;15(5):269-75.</citation>
    <PMID>18981652</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.</citation>
    <PMID>18997196</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Yuejin Yang</investigator_full_name>
    <investigator_title>Vice President of Fuwai Hospital</investigator_title>
  </responsible_party>
  <keyword>Pitavastatin</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>HbA1c</keyword>
  <keyword>LDL-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

